TRPC6介导的疾病及相关小分子调节剂的研究进展  

Research progress in TRPC6-mediated diseases and related small molecule regulators

作　　者：刘彬[1] 郭常润[1] LIU Bin;GUO Chang-run(China Pharmaceutical University,Nanjing 211198)

机构地区：[1]中国药科大学,南京211198

出　　处：《中南药学》2024年第10期2702-2709,共8页Central South Pharmacy

基　　金：长沙市揭榜挂帅重大科技项目(No.kq2301004)。

摘　　要：瞬时受体电位阳离子通道6(TRPC6)是瞬时受体电位离子通道家族的成员之一,在人体的各器官组织内广泛表达,参与多种生理功能。研究表明,TRPC6通道受到多种因素的调节,直接或间接地参与肾脏、心血管等疾病的病理生理过程,而随着研究的深入,越来越多小分子调节剂被发现能够影响TRPC6的活性或表达,对相关疾病起到改善作用,这些发现为开发针对TRPC6相关疾病的新型治疗药物提供了理论基础和潜在的药物靶点,本文概述了TRPC6在肾脏疾病、心血管疾病等发生发展中的重要作用,并对TRPC6介导相关疾病的作用机制进行了综述,并介绍了TRPC6小分子调节剂治疗肾脏、心血管等疾病的研究进展。The canonical transient receptor potential channel 6(TRPC6)is a member of the transient receptor potential ion channel family,which exhibits widespread expression in various organs and tissues throughout the human body and participates in diverse physiological functions.Numerous studies have demonstrated that TRPC6 channels are subject to regulation by multiple factors and directly or indirectly contribute to the pathophysiological processes associated with renal and cardiovascular diseases.Moreover,as research progresses,more small molecule modulators have been identified that can influence the activity or expression of TRPC6,thereby exerting beneficial effects on related diseases.These findings offer a theoretical foundation and potential targets for developing novel therapeutic drugs targeting TRPC6-related diseases.This article provided an overview of the pivotal role of TRPC6 in the development of renal and cardiovascular diseases,and reviewed diseases mediated by TRPC6 as well as their associated small molecule regulators.

关 键 词：TRPC6 肾脏 心血管 小分子调节剂 

分 类 号：R96[医药卫生—药理学]